Advanced Enzyme Technologies Q1 EBITDA Falls to ₹510M; Buyback Approved at ₹500/Share
Advanced Enzyme Technologies reported Q1 consolidated EBITDA of ₹510 million versus ₹564 million year-on-year, with EBITDA margin contracting to 26.84% from 30.36%. Consolidated net profit attributable to shareholders stood at ₹371 million against ₹399 million in the prior year period, while revenue from operations grew to ₹1.9 billion. The Board also approved a share buyback at up to ₹500 per share with an aggregate size not exceeding ₹697,000,000, along with subsidiary stake acquisition and fund infusion decisions.
*this image is generated using AI for illustrative purposes only.
Advanced Enzyme Technologies Limited's Board of Directors, at its meeting held on August 08, 2026, approved a share buyback, the acquisition of the remaining stake in a subsidiary, additional fund infusion in a wholly owned subsidiary, and the unaudited financial results for the quarter ended June 30, 2026. The board meeting commenced at 10.00 a.m. and concluded at 11.15 a.m.
Q1 Operating Performance
Advanced Enzyme Technologies reported consolidated EBITDA of ₹510 million for Q1, compared to ₹564 million in the corresponding quarter of the previous year, reflecting a year-on-year decline. The EBITDA margin contracted to 26.84% from 30.36% in the same period last year. On a consolidated basis, net profit attributable to shareholders stood at ₹371 million versus ₹399 million year-on-year, while revenue from operations grew to ₹1.9 billion from ₹1.85 billion in the prior year period.
Consolidated Financial Results — Quarter Ended June 30, 2026
The Board approved the unaudited consolidated financial results for the quarter ended June 30, 2026. The results were reviewed by the statutory auditors, who expressed an unmodified conclusion. Key consolidated financials are presented below (₹ in million except per share data):
| Metric: | Q1 FY27 (Jun 30, 2026) | Q4 FY26 (Mar 31, 2026) | Q1 FY26 (Jun 30, 2025) |
|---|---|---|---|
| Revenue from Operations: | 1,897.88 | 2,033.67 | 1,859.14 |
| Other Income: | 130.21 | 72.28 | 88.50 |
| Total Income: | 2,028.09 | 2,105.95 | 1,947.64 |
| Total Expenses: | 1,492.83 | 1,509.04 | 1,398.64 |
| Profit Before Tax: | 535.26 | 598.04 | 549.00 |
| Net Profit: | 385.89 | 452.52 | 404.40 |
| Total Comprehensive Income: | 371.62 | 931.85 | 442.11 |
| Basic EPS (₹, not annualised): | 3.31 | 3.84 | 3.57 |
| Diluted EPS (₹, not annualised): | 3.31 | 3.84 | 3.57 |
Net profit attributable to shareholders of the Company stood at ₹370.93 million for the quarter ended June 30, 2026, compared to ₹399.30 million in the corresponding quarter of the previous year. Non-controlling interest accounted for ₹14.96 million of the net profit.
Standalone Financial Results — Quarter Ended June 30, 2026
On a standalone basis, the company reported the following key figures (Rs. in million except per share data):
| Metric: | Q1 FY27 (Jun 30, 2026) | Q4 FY26 (Mar 31, 2026) | Q1 FY26 (Jun 30, 2025) |
|---|---|---|---|
| Revenue from Operations: | 1,158.57 | 1,164.10 | 1,250.24 |
| Other Income: | 22.87 | 51.63 | 538.52 |
| Total Income: | 1,181.44 | 1,215.73 | 1,788.76 |
| Total Expenses: | 884.03 | 927.30 | 974.80 |
| Profit Before Tax: | 297.41 | 288.43 | 813.96 |
| Net Profit: | 223.46 | 222.95 | 739.81 |
| Total Comprehensive Income: | 223.46 | 227.47 | 739.81 |
| Basic EPS (₹, not annualised): | 2.00 | 1.99 | 6.61 |
| Diluted EPS (₹, not annualised): | 1.99 | 1.99 | 6.61 |
Share Buyback via Open Market Route
The Board approved the buyback of fully paid-up equity shares having a face value of ₹2 each at a price not exceeding ₹500 per equity share. The aggregate buyback size shall not exceed ₹697,000,000. The buyback will be conducted from shareholders other than Promoters, the Promoter Group, and Persons in Control of the Company, payable in cash via the "Open Market" route through the Stock Exchange mechanism, in accordance with the SEBI (Buy-Back of Securities) Regulations, 2018 and the Companies Act, 2013.
At the Maximum Buyback Size and Maximum Buyback Price, the indicative maximum number of equity shares to be bought back is 1,394,000, representing 1.24% of the existing paid-up equity capital. The Maximum Buyback Size represents 9.99% and 5.09% of the aggregate of the total paid-up equity share capital and free reserves based on the latest audited Standalone and Consolidated financial statements as on March 31, 2026, respectively. The Board has also constituted a Buyback Committee and delegated its powers accordingly. A public announcement setting out the process, timelines, and other statutory details will be released in due course.
The pre and post buyback shareholding pattern (assuming buyback of maximum 1,394,000 equity shares at ₹500 per share) is as follows:
| Category: | Pre-Buyback Shares | Pre-Buyback % | Post-Buyback Shares | Post-Buyback % |
|---|---|---|---|---|
| Promoter and Promoter Group: | 48,419,510 | 43.24 | 48,419,510 | 43.79 |
| Public Shareholders: | 63,556,640 | 56.76 | 62,162,640 | 56.21 |
| Total: | 111,976,150 | 100 | 110,582,150 | 100 |
Pre-buyback figures as on July 31, 2026.
Subsidiary Developments
The Board also approved two significant subsidiary-related decisions:
- JC Biotech Private Limited (JCB): Acquisition of the remaining 4.28% equity stake (886,544 equity shares) from other existing shareholders at ₹90 per equity share, for a total consideration of ₹79.79 million. Upon completion, JCB will become a wholly owned subsidiary. The indicative timeline for completion is September 30, 2026. JCB is engaged in manufacturing and sale of bio-pharmaceuticals through aerobic fermentation, incorporated on December 31, 1991. Its turnover for FY 2026, FY 2025, and FY 2024 was ₹728 million, ₹600 million, and ₹627 million, respectively.
- Advanced Nutrazyme Private Limited (ANPL): Infusion of additional funds not exceeding ₹20 million, in one or more tranches, by way of equity investment or inter-corporate deposit. ANPL is a wholly owned subsidiary engaged in marketing and selling of nutraceutical products, incorporated on July 04, 2025. The indicative timeline for completion is December 31, 2027.
Dividend and Other Corporate Updates
The Board had proposed a final dividend of Rs. 1.35 per equity share for the financial year 2025-26, which was approved by shareholders at the Annual General Meeting held on July 31, 2026, and paid on August 5, 2026. During the quarter ended June 30, 2026, the company allotted 49,350 equity shares to employees under the Employee Stock Option Scheme 2022. The company operates in a single business segment, namely manufacturing and sales of enzymes.
Historical Stock Returns for Advanced Enzyme Tech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.65% | +5.93% | +0.51% | +12.84% | +5.36% | -21.26% |
How will the ₹697 million share buyback impact Advanced Enzyme Technologies' liquidity position and future capital allocation strategies amidst declining EBITDA margins?
What strategic synergies does the company expect to unlock by fully consolidating JC Biotech, and how will this affect its bio-pharmaceutical revenue growth trajectory?
Given the YoY decline in consolidated EBITDA despite revenue growth, what operational cost pressures or pricing challenges is the enzyme manufacturing segment facing?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
